Eli Lilly, Taikang and Tencent are in line to exit the diabetes equipment maker, which has filed to go public in Hong Kong next week.

Itochu, Qualcomm, Hearst, Catholic Health Initiatives, TriZetto and IBM are all set to exit the health plan platform developer.

Congruent Ventures has achieved an exit through the purchase of Blueprint Power by BP.

Corporate-backed cloud networking software provider Pluribus pushed its total funding to at least $110m while IAG has exited Hyper Anna in an acquisition by Alteryx.

Quanta Services is contributing to a PIPE deal for the IAC-backed internet service provider’s reverse takeover valuing the combined business at $1.66bn.

Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.

The dental technology developer’s proposed listing on the New York Stock Exchange would mark an exit for Henry Crown and Company.

The Ariad Pharmaceuticals-backed cancer therapeutics developer floated at the top of its range following $120m in venture funding.

Having priced its shares at the top of its range, UChicago spinout Pyxis Oncology suffered a drop on the first day of trading.

Ouster has bought the Congruent Ventures-backed lidar technology developer and will restructure the business as a wholly-owned subsidiary called Ouster Automotive.